Abstract
To date, pharmacological treatment of Parkinson’s disease has been symptomatic. Available agents serve to either increase striatal dopamine activity (e.g., levodopa, dopamine agonists, monoamine oxidase inhibitors, catechol-O-methyl transferase inhibitors and amantadine) or decrease acetylcholine activity. Orally disintegrating carbidopa/levodopa tablets provide bioequivalent carbidopa/levodopa in an alternative dosage form that patients prefer. The orally disintegrating tablets are useful for patients who cannot swallow a traditional oral tablet formulation and are convenient for those who do not have access to water when they need to take a dose of medication.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
